NovaScan
Easy to use ex vivo and in vivo cancer detection that provides instantaneous, highly accurate results.
Chicago, United States
16 employees
Convertible Note
Total: $7.48M
Biotechnology, Health Care +1
General Information
Get notified when NovaScan moves
Funding, new markets, leadership changes, hiring surges — one e-mail, only when something happens.
Track NovaScan
Get real-time alerts for funding, hiring, news, and 40+ signal types.
See how it worksDiscover More
United States Market
Biotechnology
About NovaScan
Taxonomy: oncology diagnostic, real-time cancer detection, clinical-stage, Cole Relaxation Frequency, point-of-care testing, cancer stratification, clinical trials, cancer diagnosis, patient outcomes, physician efficiency, cancer research, point-of-care diagnostics, innovative medical technology
Funding Rounds & Investors (9)
View All| Funding Stage | Amount | Investors | Lead Investors | Date |
|---|---|---|---|---|
| Convertible Note | •••••• | 4 |
|
22 Jan 2021 |
| Series A | •••••• | 1 |
|
01 Dec 2019 |
| Venture Round | •••••• | - | 08 May 2017 | |
| Venture Round | •••••• | - | 24 May 2016 | |
| Grant | •••••• | 1 |
|
20 Apr 2016 |
NovaScan Alternatives & Competitors
Multidisciplinary care planning for every cancer patient.
We use proprietary biomarkers to develop non-invasive immunodiagnostic kits for the diagnosis of uro...
FAQ About NovaScan
Don't just browse. Track.
Signal Tracker monitors NovaScan and millions of companies for funding rounds, hiring surges, product changes, and 40+ signal types — so you never miss an opportunity.